Ayala Pharmaceuticals Inc (ADXS)

[ubmmg]

Even if the FDA approves the SPA for Aim2Cerv trial to allow for an interim readout or smaller enrollment (lower p-value), we are still at least 2 years away from a possible interim read-out. Current timelines are as follows:
Estimated Primary Completion Date : June 2023
Estimated Study Completion Date : October 2024
The company won't be able to survive that long without a cash influx of at least $80M. Yes, they can decide to sell/partner the cervical program, but could they? So far, there have been no takers. The SPA modification approval will not little to this stock. We could get a pop that would fade by the end of the trading day. Unless they sell this program, it will be a drag and a cash burner. They really need to partner HOT and repartner NEO -- that should be their priority. I do not see any urgency, or any life left in this company. Slow death by thousands of cuts. We all made mistake buying in into this pump.